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ABSTRACT  
Neuroinflammation is increasingly recognized as a key factor in the pathogenesis of 
neurodegenerative conditions. However, it remains unclear whether it has a protective or damaging 
role. Studies of Alzheimer’s disease and Parkinson’s disease have provided much of the evidence for 
inflammatory pathology in neurodegeneration. Here we review the evidence for inflammation in 
dementia with Lewy bodies and Parkinson’s disease dementia.  
Neuroinflammation has been confirmed in vivo using PET imaging, with microglial activation seen in 
Parkinson’s disease dementia and recently in dementia with Lewy bodies. In Parkinson’s disease and 
Parkinson’s disease dementia, microglial activation suggests a chronic inflammatory process, 
although there is also evidence of its association with cognitive ability and neuronal function.   
Alpha-synuclein in various conformations has also been linked to activation of microglia, with a broad 
range of components of the innate and adaptive immune systems associated with this interaction.  
Evidence of neuroinflammation in Lewy body dementia is further supported by pathological and 
biomarker studies.  Genetic and epidemiological studies support a role for inflammation in Parkinson’s 
disease, but have yet to provide the same for Lewy body dementia.  
This review highlights the need to identify whether the nature and extent of microglial activation in 
Lewy body dementia can be linked to structural change, progression of domain specific cognitive 
symptoms and peripheral inflammation as a marker of central microglial pathology. Answers to these 
questions will enable the evaluation of immunotherapies as potential therapeutic options for 
prevention or treatment of dementia with Lewy bodies and Parkinson’s disease dementia. 
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INTRODUCTION 
Lewy body dementias (LBDs) include the closely related conditions of dementia with Lewy bodies 
(DLB) and Parkinson’s disease dementia (PDD). The clinical syndrome of DLB forms at least 4.2% of 
all dementia patients and is second only to Alzheimer's disease (AD) as a cause of degenerative 
dementia in older people[1]. Dementia also develops in over 80% of those with Parkinson’s disease 
(PD)[2], a disorder where Lewy bodies play a prominent role, with PDD forming 3.6% of all dementia 
cases[3]. Autopsy studies of dementia cases have estimated the combined prevalence rate of LBDs 
to be even higher, at around 20%[4,5]. 
The etiology of LBDs is unclear, but a role for chronic neuroinflammation has been proposed, 
analogous to the emerging evidence for inflammation in the etiology of AD. The evidence to date for 
AD includes neuropathological studies with evidence of brain inflammation, Positron Emission 
Tomography (PET) imaging displaying microglial activation in vivo, genetic studies implicating 
polymorphisms in genes involved in the inflammatory response as risk factors, epidemiological 
studies indicating a protective effect of non-steroidal anti-inflammatory drugs (NSAIDs) and mouse 
models of AD in which NSAIDs reduced neuroinflammation and protein deposition[6–9].  
In light of the gathering evidence for neuroinflammation in AD, we asked whether neuroinflammation 
is also involved in the etiology of LBDs. We review the literature for evidence of neuroinflammation in 
Parkinson’s disease dementia and dementia with Lewy bodies, across multiple methodologies. 
 
LITERATURE SEARCH STRATEGY  
References were identified using searches of PubMed with key words. The following combinations 
were used in a search of titles and abstracts in June 2015 (the number of articles yielded is noted in 
brackets): 
1. ‘Lewy’ and (‘inflammation’ OR ‘neuroinflammation’) (98 articles)  
2. (‘Parkinson's disease dementia’ OR ‘PDD’ OR ‘DLB’ OR (‘Dementia AND Parkinson*’)) AND 
(‘neuroinflammation’ OR ‘inflammation’) (283 articles)  
3. ‘synuclein’ AND ‘microglia’ (185 articles) 
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4. ‘synuclein’ AND (‘inflammation’ OR ‘neuroinflammation’) (210 articles) 
The abstracts of these articles were screened and full texts of those potentially relevant articles to the 
review were obtained. In order to ensure that all relevant references were sourced, references were in 
turn reviewed for other relevant articles, supplemented by articles known to the authors.  
 
MICROGLIAL FUNCTION  
Neuroinflammation describes the response to injury within the central nervous system (CNS) leading 
to the activation of microglia and astrocytes, release of cytokines and chemokines, invasion of 
circulating immune cells and complement activation. Microglia are the resident macrophages of the 
CNS, originating from progenitors in the embryonic yolk sac[10]. They provide the innate immune 
response to invading pathogens and also initiate the adaptive response through antigen 
presentation[11].  
Microglia are resting or “inactivated” under physiological conditions with characteristic ramified 
morphology and distributed within brain regions, such that rami are close but not touching, implying 
each cell has its own distinctive territory. But even in this inactive state, they have been shown using 
two-photon microscopy to be continuously monitoring the extracellular spaces with their processes 
and protrusions in adult mice[12]. Activation leads to morphological change to a more rounded 
amoeboid shape, with targeted movement of processes towards sites of injury or stimuli to initiate 
phagocytosis[12] and leads to production of chemokines, that amplify the response by recruiting other 
microglia, plus cytokines, free radicals and proteases which destroy infectious organisms and infected 
neurons. 
Microglia appear to have an important part both in MPTP disease progression and idiopathic PD[13], 
suggesting a central role for these glia in nigro-striatal degeneration, irrespective of etiology. Microglia 
may be especially susceptible to mechanisms of aging. Their maintenance is proposed to be 
dependent on self-renewal rather than replenishment by peripheral blood precursors[14,15], which 
could be highly significant in age dependent neurodegenerative conditions such as LBD. Systemic 
infections or disease, which rise in number with age, could also lead to priming of microglia, such that 
their response is exaggerated and damaging to nearby neurons leading to cognitive decline[16]. It has 
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also been proposed that an initial stimulus that triggers microglial activation could persist in 
neurodegenerative disorders leading to repeated cyclical chronic neuroinflammation causing neuronal 
dysfunction and cell death[17,18]. The specificity of these changes to Lewy body dementias is 
unclear. 
 
IMAGING EVIDENCE OF NEUROINFLAMMATION AND NEURONAL DYSFUNCTION  
Imaging studies have shown an association between neuroinflammation in vivo and cognitive 
dysfunction. Microglial activation as a marker of neuroinflammation has been identified in PD and 
PDD[19] (see Table 1) using [
11
C]-RPK11195 (RPK11195), a PET ligand that binds to a translocator 
protein found on microglia in their activated state. Extensive microglial activation has similarly been 
identified in another α-synucleinopathy: multiple systems atrophy[20], as well as other degenerative 
conditions, including AD[21,22]. 
An association between microglial activation in the midbrain and dopaminergic loss in the dorsal 
putamen has been found in the early stages of PD (less than 2.5 years), both contralateral to the 
clinically affected side, with levels of activation correlating with severity of motor impairment measured 
by the Unified Parkinson’s Disease Rating Scale (UPDRS)[23]. In the later stages of disease (disease 
duration range 0.5 - 21 years), there is extensive microglial activation, with the basal ganglia, cortex 
and pons all showing significantly increased levels. The substantia nigra was however spared. Follow-
up scans in eight of these subjects (after 18-28 months) showed no significant change in microglial 
activation from baseline despite a clear deterioration in disability as measured using the UPDRS. 
Cognition was however not assessed longitudinally[24]. The authors also noted a clear overlap in the 
areas of microglial activation and the regions proposed by Braak et al.[25] in their study of PD 
pathology. In PDD subjects, there is increased cortical microglial activation compared to control 
subjects, however levels of activation were also increased in comparison to PD cases – in the left 
parietal lobe[26].  
In DLB, increased microglial activation in the substantia nigra and putamen, plus several cortical 
regions was found in a pilot imaging study of six cases of less than one year’s duration[27]. That 
microglial activation occurs in more widespread regions in early DLB, where there is greater cognitive 
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dysfunction compared to early PD, strengthens the link between microglial activation and cognitive 
decline.  
A relationship between microglial activation and cognitive function was indeed found in PDD, where 
cortical activation levels inversely correlated with MMSE in temporo-parietal, occipital, and frontal 
cortical regions[19,26]. Fan et al.[19] demonstrated a significant negative correlation between whole 
brain levels of microglial activation and glucose metabolism. Within the temporo-parietal cortex there 
was voxel by voxel significant inverse correlation between levels of microglial activation and glucose 
metabolism in the immediate vicinity suggesting local damage, but the areas of correlation were 
small. The authors however suggest distant microglial activation could be linked to cell dysfunction in 
the medial temporal lobe through pre-existing neuronal pathways. Neither study of PDD assessed 
whether areas of increased activation (such as in the hippocampus) were linked to dysfunction in 
specific cognitive domains (such as memory), which may have provided a stronger link between 
inflammation and cognitive dysfunction. 
Small clusters of positive correlations were also found between RPK11195 binding and amyloid load 
(as determined by [
11
C] Pittsburgh compound B (PIB), a marker of fibrillary amyloid load) in PDD 
subjects, but only in the parietal lobe and anterior cingulate, as opposed to AD subjects in whom there 
was a stronger correlation between amyloid load and microglial activation. There was however little 
amyloid deposition found in PDD cases overall[19]. Proteins other than amyloid, such as α-synuclein 
or tau, could be triggering microglial activation in PDD, however currently there are no α-synuclein 
PET ligands available to demonstrate this and tau ligands have only very recently become available.  
Overall small scale studies with in vivo imaging have suggested that in PD, PDD and in a small 
preliminary report of DLB, there is early microglial activation. But, this does not appear to increase 
over time. Significantly microglial activation also correlates inversely with cognitive function and to an 
extent protein deposition, suggesting microglia may have a crucial role in the pathogenesis of these 
conditions.  
ALPHA SYNUCLEIN AND NEUROINFLAMMATION 
The evidence for extensive microglial activation in LBDs, in an immunologically privileged site such as 
the brain, is highly significant. Immune responses are tightly controlled and yet there is widespread 
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glial cell activation, present chronically during the disease. The initiation of the innate response occurs 
through pattern-recognition receptors (PRRs) expressed on CNS cells (for example the toll-like 
receptor (TLR)) through activation by pathogen associated molecular patterns or danger associated 
molecular patterns. However α-synuclein is the main component of Lewy bodies[28] which 
characterize LBDs, and the driving force behind the disease process, hence the interaction between 
this protein and microglia appears to be critical. Alpha-synuclein inclusions in neurons and glia are 
associated with DLB and PDD, as well as PD and multiple system atrophy. In DLB and PDD, the 
inclusions are neuronal and in the form of Lewy bodies[28]. Lewy neurites are also common in these 
disorders, consisting of coarse dystrophic neurites immunoreactive for α-synuclein within affected 
neurons.  With 140 amino acids, α-synuclein’s possible intracellular forms include monomeric[29,30] 
or relatively stable folded tetramer[31,32].  
Alpha-synuclein, has been shown repeatedly to activate microglia and induce dopamine cell loss[33–
35], including monomeric wild-type and mutant forms as well as extracellular oligomeric 
conformations. Indeed, neuron-glia cultures depleted of microglia have been shown to be resistant to 
α-synuclein induced dopaminergic neurotoxicity[33]. More recently the focus has moved on to 
possible mechanisms. Models of PD have been used to study this relationship rather than models of 
DLB, with overexpression of α-synuclein in the substantia nigra using viral vectors, the most common.  
A survey of the literature shows several possible mechanisms for this interaction (see Table 2).  
A number of immunomodulatory proteins and compounds are implicated in α-synuclein microglial 
recognition, chemotaxis, activation and response. TLRs 1[36], 2[36,37] and 4[38] are PRRs key to the 
innate response machinery and have been reported as having a role in recognition of α-synuclein by 
microglia. Microglia exposed to higher-ordered oligomers (but not monomers) of α-synuclein changed 
to an amoeboid, phagocytic morphology with increased secretion of Tumor Necrosis Factor α (TNF-α) 
that was reduced by inhibition of the TLR 1/2 complex [36]. A separate study found only β-sheet rich 
oligomeric conformations of α-synuclein could activate microglia via TLR 2, but both aggregated and 
non-aggregated forms could activate microglia through TLR 4. Furthermore pro-inflammatory 
cytokine/chemokine release was completely eliminated in TLR 2 knockout mouse microglia exposed 
to α-synuclein, but remained unaffected in TLR 4 knockout mouse microglia[39], suggesting TLR 2 
recognition of oligomeric α-synuclein leads to inflammation.  
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Another molecule which could feature in the initiation of microglia activation is Fractalkine, a 
membrane bound chemokine which acts on the CX3CR1 receptor on microglia to suppress 
production of inflammatory molecules. A soluble secreted form of Fractalkine had a protective function 
in an animal model of α-synuclein overexpression, suggesting loss of this membrane bound 
chemokine could lead to neuronal loss through microglia mediated cell damage[40].  
Αlpha-synuclein, in extracellular aggregated form, has been shown to be a chemoattractant through 
CD11b receptors on microglia[41]. Also, the β1-integrin subunit, which forms transmembrane 
adhesion molecules has been reported as being required for the morphological changes and 
migration of microglia seen in the presence of extracellular α-synuclein[42].  
Once microglia are activated, Interleukin-1 (IL-1) appears to be a key cytokine in promoting an 
inflammatory response. IL-1α and β knockout mice did not show loss of dopamine neurons or 
behavioral deficits seen in wild-type mice in a mouse model of PD, utilizing lipopolysaccharide(LPS) 
injections into the substantia nigra.  LPS injections have been shown to produce microglial activation, 
cytokine release and subsequent dopaminergic cell loss in the substantia nigra[43]. TNF-α knockout 
mice however showed similar results to wild-type mice[44], indeed TNF-α  may have role in promoting 
α-synuclein accumulation[45]. Galectin-3 has also been shown to be important for the inflammatory 
effect of α-synuclein. Its inhibition significantly reduced cytokine release by microglia in response to 
aggregated α-synuclein[46].  
Leucine-rich repeat kinase 2 (LRRK2) is a protein expressed on microglia when they are in their 
inflammatory state and has been shown to have a significant role in α-synuclein mediated microglial 
activation and subsequent cell loss, with LRRK2 knockout mice being protected from α-synuclein 
overexpression[47]. Another protein involved is NRF2, which is a transcription factor for a number of 
cell protection proteins and appears to have a protective role in the interaction[48].  
Several studies suggest the adaptive immune response is engaged by microglia following their 
activation. Knockout mice without Fc gamma receptors (FcγR), which are found on microglia and 
involved in facilitating phagocytosis through binding of IgG, showed reduced pro-inflammatory 
signaling in the presence of aggregated α-synuclein. Suggesting the latter could be triggering 
inflammation and antibody mediated cell damage through FcγR[49]. In addition, a knockout of all four 
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murine MHC II complex genes prevented α-synuclein induced dopaminergic cell loss in a mouse 
model, strongly suggesting that CD4 T lymphocytes are critical to α-synuclein cell damage. Microglia, 
as the only resident cells expressing MHC class II in the CNS, would be candidates for their 
recruitment, although infiltrating antigen presenting cells such as macrophages may also be 
involved[50]. Furthermore, mice with microglia deficient in Prostaglandin E2, which is thought to have 
a role in lymphocyte proliferation, have increased resistance to MPTP mediated pathology[51].   
 
PATHOLOGICAL EVIDENCE OF INFLAMMATION 
Pathological studies further support a role for inflammation. Large numbers of HLA-DR-positive 
microglia, indicating reactive states, have been reported in the substantia nigra of PD and PDD cases 
together with Lewy bodies in association with a reduction in dopaminergic cells. In the PDD cases 
HLA-DR positive microglia were also found in the hippocampus, though this was associated with 
neuritic plaques and tangles suggestive of AD pathology[52]. Involvement of the transenterohinal, 
cingulate and temporal cortices in PD has also been identified. Activated microglia in these regions 
also expressed MHC Class II molecules, HLA-DP, DQ and DR[53]. The presence of CD4 (as well as 
CD8) T lymphocytes within the substantia nigra of PD cases at post-mortem has subsequently been 
confirmed[54]. In addition, concentrations of interleukin-1β, interleukin-6 and transforming growth 
factor-α are higher in the striatal regions of post-mortem PD brains compared to controls[55]. 
Complement proteins are also found with Lewy bodies within this region in PD[56].  
In DLB, both complement proteins and microglial interaction are associated with Lewy body 
containing degenerated neurons on autopsy, suggesting microglial involvement[57]. An increase in 
activated microglia has also been reported in DLB cases, positively correlating with the number of 
Lewy bodies also seen regionally[58]. However this was not as high as in those cases with 
concomitant senile plaques and a second study has shown a lack of significant microglial activation in 
the absence of tau neuritic plaques in DLB[59]. The link between microglial activation and 
pathological protein deposition in both PDD and DLB is therefore not fully established.  
 
EVIDENCE FROM GENETIC STUDIES 
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Genetic studies have identified polymorphisms in genes coding IL-1β, TNF-α and Triggering Receptor 
Expressed on Myeloid cells 2 (TREM2)  as risk factors for PD. Up to a doubling of risk has been 
reported amongst carriers of a genotype of IL-1β that is associated with increased gene 
expression[60,61].  Those carrying the homozygous variant genotype TNF-α-308, a variant which is 
thought to be a stronger transcriptional activator, experience doubled risk[60]. Overall the results from 
these two small studies are consistent with a gene dosing effect for these two powerful cytokines. A 
rare variant of the microglial receptor TREM2, that leads to loss of function, was found to be another 
risk factor for PD in a study of 1493 cases compared to 1957 controls[62].  
Genome wide association studies (GWAS) provide further evidence for inflammatory pathology in PD. 
Polymorphisms in HLA regions that code segments of the MHC class II molecule present increased 
risk. A strong association was found within noncoding intron 1 of HLA-DRA (in a study of 2000 cases 
and 1986 controls) by Hamza and colleagues[63], with subsequent large-scale meta-analyses of 
single nucleotide polymorphisms(SNP) confirming associations amid the HLA-DR locus, with both 
HLA-DRB5[64] and HLA-DQB1[65] identified. Wissemann and colleagues[66] found loci that 
predisposed to, as well as protected from, PD within the same 2000 PD and 1986 control GWAS 
dataset initially analyzed by Hamza et al. [63], and replicated these in a further 843 cases and 856 
controls. The strongest association was again intron 1 of the HLA-DRA region, which regulates gene 
expression and linked to increased risk. This suggests HLA expression levels may play a key role in 
determining risk for PD. Indeed subjects homozygous for the G allele in this SNP, were found to have 
significantly increased MHC class II expression, compared to subjects who did not have a single G 
allele. In addition, exposure to a common insecticide, pyrethroid, when combined with possession of 
the GG allele, significantly increased PD risk[67], suggesting a combination of environmental triggers 
and inflammatory processes may play a part in PD pathology. 
Notwithstanding the accumulated genetic evidence in the context of PD, the equivalent associations 
in DLB have not been established, although methods of investigation may need to be broadened, as 
studies have been limited so far[68]. Polymorphisms in genes associated with inflammation are also 
yet to be identified as risk factors for PDD specifically. 
 
EVIDENCE FROM BLOOD BIOMARKERS 
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Elevated peripheral inflammatory markers both before and after the onset of PD, suggest 
inflammation is concurrent with the disease. Increased plasma interleukin-6 (IL-6), measured on 
average 4.3 years before diagnosis, is associated with increased risk of developing PD, with higher 
levels associated with higher risk[69]. After disease onset, levels of IL-6[70,71], IL-1β[71]  and TNF-
α[70] are elevated compared to controls in PD, as is RANTES (regulated on activation, normal T cell 
expressed and secreted), a chemokine which attracts T-cells. RANTES levels also correlated with 
motor symptom severity[72]. A change in peripheral blood lymphocyte subsets further suggests a role 
for the adaptive immune system. A decrease in the overall level of T-helper CD4 cells but a rise in the 
subset of activated T-helper cells is reported in PD cases compared to controls[73].  
In PDD, high sensitivity CRP is increased compared to controls, but a significant elevation was not 
found in PDD compared to PD[74]. Peripheral markers suggestive of inflammation are yet to be found 
in DLB. Therefore the blood biomarkers evidence for inflammation in LBDs is inconclusive. 
 
EVIDENCE FROM CEREBROSPINAL FLUID BIOMARKERS 
Attempts to identify a reliable cerebrospinal fluid (CSF) biomarker for PD or PDD have so far been 
inconsistent. The main candidates include total α-synuclein, Aβ42, and β-Glucocerebrosidase[75]. 
Inflammatory cytokines TNF-α[76], IL-6[77,78] and IL-1β[71,77]  have also been investigated with 
raised levels seen in the CSF of PD cases compared to controls. IL-1β levels in the CSF were 
associated with raised α-synuclein oligomers also in the CSF, suggesting a direct link with protein 
deposition[71]. 
In a study of 22 cases of PD, IL-6 was found to associate inversely with disease severity as assessed 
by the UPDRS[78]. In a larger study of 62 cases, IL-6 was elevated in cases of PD with cognitive 
impairment compared to those without, the levels being negatively correlated to cognitive function. 
TNF-α and Interferon γ levels were however reduced in those with cognitive impairment in PD 
compared to control subjects[79]. A rise in the fractalkine:Aβ42 ratio in CSF is also associated with 
motor severity of PD (again measured by UPDRS) but not with disease duration[80]. An increase in 
this ratio could suggest increased inflammatory signaling and microglial activation. An increase in 
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Leucine rich α2-glycoprotein (LRG), thought to be a marker of inflammation, is reported in the CSF 
and post-mortem tissue of PDD and DLB cases, compared to controls[81]. 
The focus in DLB has been on the variations of Aβ peptides and tau as well as α-synuclein; a 
combination of biomarkers may be the best route to increase specificity and sensitivity[82,83].  The 
inflammatory marker Procalcitonin has been found to be significantly raised in dementia subjects 
within the CSF, compared to controls, with the highest median level found in DLB cases[84].  
 
EVIDENCE FROM EPIDEMIOLOGICAL STUDIES  
There is limited support for neuroinflammation in PD from epidemiology studies. A meta-analysis of 
the association of NSAIDs and the risk of developing PD, showed a 15% reduction in incidence 
among users of non-aspirin NSAIDS, with analysis of ibuprofen alone showing a stronger protective 
effect. This effect was more pronounced among regular users[85]. Whether PDD incidence was lower 
in those who developed PD despite taking NSAIDS was not considered.  
A further meta-analysis showed conflicting results with no overall protective effect, however there 
were methodological differences including the inclusion of aspirin and studies where NSAID exposure 
was entirely within a 1 year of the diagnosis of PD. Nevertheless a slight protective effect for 
ibuprofen in lowering the risk of PD was still confirmed[86]. The evidence from these studies is 
however difficult to interpret because of variations in the drugs investigated, the duration of the drug 
treatment and the timing of administration in relation to disease onset.  
Whether NSAIDs could reduce the risk of developing DLB or protect those with PD from developing 
dementia, has not yet been established. 
 
A ROLE FOR THE ADAPTIVE IMMUNE SYSTEM 
Despite the evidence of microglial activation and an interaction between α-synuclein and microglia, 
the precise mechanism and whether it is always detrimental to neurons remains unclear. A paucity of 
the relationship between Lewy bodies and antigen presenting activated microglia in post mortem 
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studies was reported by Imamura et al.[53], indeed there was only a 20% association. This would 
suggest that Lewy bodies alone are not sufficient in themselves to trigger antigen presentation by 
microglia. In addition, increasing neuronal loss in the substantia nigra with lengthening disease 
duration was not associated with an increase in microglial activation, implying a steady rather than 
escalating inflammatory response[87].  
Orr and colleagues[87] also demonstrated that substantia nigra neurons were immunopositive for IgG 
in PD, whereas control cases’ substantia nigra neurons as well as the visual cortex of PD cases 
showed negative immunoreactivity. Neuronal IgG labelling related to the degree of neuronal loss and 
microglial activation, with the authors suggesting humoral immune system involvement in the 
selective destruction of substantia nigra neurons.  
Given that the MHC class II complex has also been shown to be key in dopamine neuronal cell loss in 
mouse models[50], it may be that an adaptive immune response is the final path to neuronal loss, 
following a switch in microglia function from protective to deleterious. Consistent with this theory is the 
genetic risk associated with HLA class II gene variation previously described, as well as the alteration 
in peripheral lymphocyte subsets found in PD cases[73], and the evidence that B and T lymphocyte 
infiltration of the substantia nigra is found at post mortem[54] and in a mouse model of α-synuclein 
overexpression[35].  
It is possible initial protein clearance by microglia could be switched to a more harmful toxic function 
involving recruitment of the adaptive response ultimately leading to neuronal degeneration. For 
example due to peripheral inflammation or increased vulnerability of microglia through ageing. The 
timing of treatment initiation would be key in such circumstances.  
 
 
CONCLUSION AND FUTURE DIRECTIONS 
Evidence for the role of neuroinflammation in LBDs continues to accumulate, building on the evidence 
of neuroinflammation in AD and PD. Imaging studies lead the way in supporting neuroinflammation as 
a key part of the pathogen process in LBDs, supported by pathological and biomarker evidence, 
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though mostly in PDD. Future studies are required to further establish the presence of inflammation in 
DLB including imaging, genetic and biomarker studies. 
Involvement of microglia in LBDs is signified by the presence of activation years before neuronal 
death as revealed by in vivo imaging, as well as after cell loss in pathology specimens. Microglial 
involvement is also supported by evidence of the activation of microglia by α-synuclein. Levels of 
activation however appear to remain relatively stable, which could indicate initiation and propagation 
of the disease process by microglia or alternatively a protective function that is eventually overcome. 
In order to understand how inflammation affects disease progression in Lewy body dementia, studies 
need to try and link the nature and extent of microglial activation with important indicators of disease 
severity such as structural brain changes, protein deposition and the onset and progression of key 
cognitive and non-cognitive symptoms through longitudinal studies in established disease and in 
those at risk. 
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Table 1: Evidence of in vivo microglial activation in PD, PDD and DLB from RPK11195 PET imaging studies 
STUDY PARTICIPANT 
NUMBERS 
(controls) 
PARTICIPANT 
AGE (years) 
PARTICIPANT 
MMSE 
DISEASE 
DURATION (years) 
REGIONS WITH INCREASED MICROGLIAL ACTIVATION COMPARED TO 
CONTROLS  
Ouchi et al. 
2005 
[23] 
10 PD (10 
controls) 
 
Range: 43-72;  
Mean: 59.6 
Range: 26-30; 
Mean: 28.3 
 
Range: 0.4-2.5;  
Mean: 1.4 
Midbrain contralateral to the clinically affected side 
Iannaccone 
et al. 2013 
[27] 
6 PD (11 
controls) 
Range: 60-74 ; 
Mean: 70.2 
Range: 27-30; 
Mean: 29  
Range: 0.6-1; 
Mean: 0.8 
Putamen,  substantia nigra 
Gerhard at 
al. 2006 [24] 
18 PD (11 
controls) 
Range:  50-69; 
Mean: 59.2 
Not specifically 
stated, screening 
tests normal in PD 
group 
Range: 0.5-21; 
Mean: 8.6 
Striatum, pallidum, thalamus, cortex (precentral gyrus, frontal lobe, 
anterior cingulate gyrus, posterior cingulate gyrus) and pons  
Edison et al. 
2013 [26] 
8 PD  (10 
controls) 
Range: 58-75; 
Mean: 68.2 
Range: 27-30; 
Mean: 28.8 
Mean: 9.2 Cortex (temporal, parietal, and occipital regions) 
Fan et al. 
2014 [19] 
11 PDD (8 
controls) 
Range: 55-75; 
Mean: 68.4 
Mean: 22.1 Not stated Anterior cingulate gyrus, posterior cingulate gyrus, frontal lobe, temporal 
lobe, parietal lobe, occipital lobe, medial temporal lobe, amygdala and 
hippocampus  
Edison et al. 
2013 [26] 
11 PDD (10 
controls) 
Range: 56-80; 
Mean: 69.3 
Range: 16-26;  
Mean: 21.8 
PD duration mean: 
10.6; Dementia  
duration mean: 3.5 
Striatum, cortex (frontal, temporal, parietal, anterior and posterior 
cingulate gyrus, and occipital cortical regions) 
 
Iannaccone 
et al. 2013 
[27] 
6 DLB (11 
controls) 
Range: 62-82 ; 
Mean: 72 
Range: 19-30; 
Mean: 24 
Range: 0.7-1; 
Mean: 0.8 
Caudate, putamen, thalamus, substantia nigra, cortex (frontal lateral,  
parietal lateral, temporal lateral, temporal pole, precuneus, occipital 
medial, occipital lateral, anterior cingulate, posterior cingulate) and 
cerebellum  
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Table 2: Potential mechanisms of interaction between α-synuclein and microglia 
INTERACTION/ RECEPTOR PROPOSED MECHANISM OF MICROGLIAL INTERACTION 
WITH α-SYNUCLEIN 
PD MODEL REFERENCES 
TLR 1&2 complex Oligomeric α-synuclein induces a pro-inflammatory 
microglial phenotype through TLR 1/2 complex: microglia 
exposed to oligomers of α-synuclein changed to an 
amoeboid, phagocytic shape, with increased secretion of 
TNF-α and interleukin-1b. TNF-α secretion was reduced by 
the addition of a TLR-1/2 complex inhibitor or by a MyD88 
inhibitor.  
Primary microglia cultures derived from mouse 
cortices were exposed to high-order oligomeric 
forms of purified human wild-type α-synuclein 
 
[36] 
Fractalkine receptor (FKN), 
an immune regulatory 
protein 
Secreted form of FKN is neuro-protective: Soluble secreted 
form of FKN prevents reduction in tyrosine hydroxylase cell 
staining compared to controls and membrane bound FKN 
models when exposed to overexpression of α-synuclein, 
despite increased MHCII expression on microglia 
Overexpression of human α-synuclein via viral 
vector combined with a variety of viral constructs 
of FKN 
[40] 
CD11b receptor Alpha-synuclein binds to CD11b on microglia 
to direct microglial migration: neuronal α-synuclein 
overexpression led to microglial migration toward neurons, 
which was reduced by antibodies to the CD11b receptor  
and diminished in CD11b knockout mice 
Overexpression of human α-synuclein via viral 
vector in rat primary neuron-enriched cultures 
[41] 
Galectin-3 (carbohydrate-
binding protein and 
inflammatory mediator) 
Galectin 3 mediates microglial cytokine release: Release of 
Interleukin-2 and Interleukin-12 after exposure to 
monomeric and aggregated forms of recombinant α-
synuclein reduced by genetic down regulation or 
pharmacological inhibition of galectin-3 
Microglia from wild-type and galectin-3 knockout 
mice 
[46] 
Leucine-rich repeat kinase 2 
(LRRK2) 
LRRK2 required for microglial activation and dopaminergic 
degeneration: Rats lacking LRRK2 demonstrated a 
significant reduction in microglial activation compared to 
wild type mice rats, when exposed to lipopolysaccharide 
(LPS) and were protected from dopaminergic 
neurodegeneration from α-synuclein overexpression. 
Rats exposed to intracranial LPS injection or 
overexpression of human α-synuclein via viral 
vector 
[47] 
β1-integrin Migration of microglia to disease affected regions is via 
β1-integrin: β1-integrin inhibition reduced microglial 
morphological changes and motility (as shown by reduced 
wound healing)  
Rat primary microglia exposed to α-synuclein 
conditioned medium (αSCM) 
[42] 
P a g e  | 17 
 
Interleukin-1 (IL-1) IL-1 is required for microglial activation: behavioral 
deficiencies that occurred in wild-type mice, following LPS 
administration did not occur in IL-1 knockout mice. Tyrosine 
Hydroxylase gene expression was similarly preserved in in 
IL-1 knockout but not wild-type mice.  
Mouse model using intracranial LPS injection into 
wild-type and  IL-1 (α and β) knockout mice 
[44] 
MHCII Complex MHCII complex mediates microglial activation and 
dopaminergic cell loss: overexpression of synuclein leads to 
induction of MHCII expression on microglia and genetic 
knockout of MHCII prevents microglial activation, IgG 
deposition and dopaminergic cell loss in vivo 
Mouse model using overexpression of human α-
synuclein via viral vector in wild-type and MHCII 
knockout mice 
[50] 
TLR 4  TLR 4 mediates microglial phagocytic activity and cytokine 
release in the presence of α-synuclein: Microglial 
phagocytic activity was significantly reduced in TLR4 
knockout microglia mice after treatment with different 
forms of α-synuclein; knockout mice also showed 
significantly reduced TNF- α production following treatment 
with α-synuclein. 
Mouse primary microglia from wild type and TLR4 
knockout mice challenged with cloned human α-
synuclein from spinal cord cDNA 
[38] 
TLR 2 TLR 2 mediates microglial activation by oligomeric α-
synuclein: TLR2 knockout mice exhibited significantly 
lowered microglial activation compared with wild type mice 
when exposed to α-synuclein overexpression; 
cytokine/chemokine gene induction following exposure to 
αSCM, was prevented by antagonizing TLR2 and by 
depletion of the TLR2 gene; and TLR2 was only activated by 
oligomeric alpha synuclein not the dimer or monomer 
forms. 
 
Mouse model using overexpression of human α-
synuclein via viral vector in wild-type and TLR 2 
knockout mice; oligomeric human α-synuclein 
proteins released from dSY5Y cells 
[37] 
Fc gamma receptors (FcγR)  FcγR mediates α-synuclein intracellular localization to 
autophagosomes and NF-κB pro-inflammatory signaling: 
microglia internalized α-synuclein in a dense aggregated 
form in wild-type mice but a diffuse manner in FcγR 
knockout mice; FcγR knockout mice treated with α-
synuclein also failed to trigger the enhancement of nuclear 
NF-κB p65 seen when wild-type mice are exposed to α-
synuclein. 
Primary microglial cultures from wild-type and 
FcγR knockout mice, treated with human α-
synuclein 
 
[49] 
NRF2 (NF-E2-related factor NRF2 protects against α-synuclein mediated microglial Mouse model using overexpression of human α- [48] 
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2), a transcription factor activation and dopaminergic cell loss: NRF2 knockout mice 
showed increased microglial activation and greater nigral 
dopaminergic neuronal loss than wild-type mice when 
exposed to α-synuclein overexpression; NRF2 knockout 
neurons were characterized by thick dendrites loaded with 
α-synuclein, similar in appearance to Lewy neurites and this 
was associated with reduced levels of the beta subunit 
(PSMB7) of the catalytic core 20S proteasome compared to 
wild-type mice 
synuclein via viral vector in wild-type and NRF2 
knockout mice 
Prostaglandin E2 receptor 
subtype 2 (PGE2) 
PGE2 is key to regulation of aggregated α-synuclein levels: 
microglia isolated from PGE2 knockout mice exhibited 
enhanced clearance of aggregated α-synuclein and showed 
increased resistance to MPTP with less aggregated α-
synuclein in the substantia nigra and striatum. 
Aggregated  α-synuclein from human DLB cases 
incubated with wild-type and PGE2 knockout mice 
microglia 
[51] 
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